9330 Atumelnant (crn04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With Acth-Dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-Label Study
Henrik Elenius(National Institutes of Health), Lynnette K. Nieman(National Institute of Diabetes and Digestive and Kidney Diseases), Yetunde B Omotosho(National Institute of Diabetes and Digestive and Kidney Diseases), Alan Krasner(Takeda (United States)), Stephen F. Betz(Abbott (United States)), Yongning Wu(Chinese Academy of Medical Sciences & Peking Union Medical College), R. Scott Struthers(Crinetics Pharmaceuticals (United States)), Raven McGlotten(National Institutes of Health), Peter Trainer(University of Manchester), Christopher A. Moore(National Institutes of Health), Alejandro Ayala(Instituto Tecnológico de Morelia)
Cited by 5
Related Papers
The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
|The Journal of Clinical Endocrinology & Metabolism|2008|2.7k
Effects of Gonadal Steroids in Women With a History of Postpartum Depression
|American Journal of Psychiatry|2000|942
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
|New England Journal of Medicine|2000|874
Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome
|New England Journal of Medicine|1998|766
Cushing’s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years’ Experience at the National Institutes of Health
|The Journal of Clinical Endocrinology & Metabolism|2005|711